Decline in LDL-C control in patients with dyslipidemia treated with PCSK9-inhibitors: The role of obesity in LDL-C target achievement
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.06.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Elena Formisano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Genoa, Genoa, Italy (Drs Formisano, Vignati, Bertolini, Spandonari, Tafuro, Pasta, and Pisciotta); Die…. Hauptthemen laut MEDLINE: Cholesterol, LDL, PCSK9 Inhibitors, Obesity, Dyslipidemias. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-Is: alirocumab and evolocumab) have improved dyslipidemia management in patients with high cardiovascular risk. However, some patients fail to reach low-density lipoprotein cholesterol (LDL-C) targets. OBJECTIVE: To evaluate factors influencing PCSK9-I therapy effectiveness. METHODS: A retrospective study (2018-2023) analyzed adults treated with a PCSK9-I for at least 6 months with heterozygous familial hypercholesterolemia (He-FH) in primary prevention, dyslipidemia in secondary prevention, or diabetes with associated complications. Clinical, anthropometric data and lipid profiles were collected at baseline and after 6, 12, 24, and 36 months. The primary outcome was LDL-C target achievement according to European Society of Cardiology/European Atherosclerosis Society guidelines. RESULTS: Among 180 patients, approximately 45% achieved the LDL-C target. Patients with overweight and obesity showed significantly lower LDL-C reductions compared to normal-weight patients. Those reductions for overweight patients were 47.8%, 50.0%, and 44.0%, and for obese patients were 25.6%, 29.4%, and 28.6%, whereas normal-weight patients achieved reductions of 54.5% (P = .021), 62.5% (P = .024), and 65.4% (P = .024), respectively. Multivariate analysis confirmed these findings (odds ratio [OR]: 0.18, 95% CI, 0.06-0.53, P = .002) and highlighted that He-FH was associated with lower likelihood of achieving LDL-C targets (OR: 0.35, 95% CI, 0.15-0.82, P = .015). Conversely, patients with coronary artery disease (CAD) were more likely to reach LDL-C targets (OR: 4.54, 95% CI, 1.98-10.41, P < .0001). Concomitant oral lipid-lowering therapy was linked to a higher probability of achieving LDL-C targets compared to PCSK9-I monotherapy (OR: 14.5, 95% CI 2.26-92.9, P = .005). CONCLUSION: Overweight, He-FH, CAD, and concomitant oral lipid-lowering therapy could influence the achievement of LDL-C target in patients treated with PCSK9-Is.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Genoa, Genoa, Italy (Drs Formisano, Vignati, Bertolini, Spandonari, Tafuro, Pasta, and Pisciotta); Dietetics and Clinical Nutrition Unit, IRCCS Policlinic Hospital San Mart…
- Department of Internal Medicine, University of Genoa, Genoa, Italy (Drs Formisano, Vignati, Bertolini, Spandonari, Tafuro, Pasta, and Pisciotta).
- Dietetics and Clinical Nutrition Unit, IRCCS Policlinic Hospital San Martino, Genoa, Italy (Drs Formisano, Sukkar, and Pisciotta).
Zitieren
APA
Formisano, E., Vignati, A., Bertolini, A., Barreto Spandonari, V. M., Tafuro, M., Pasta, A., Sukkar, S. G., & Pisciotta, L. (2025). Decline in LDL-C control in patients with dyslipidemia treated with PCSK9-inhibitors: The role of obesity in LDL-C target achievement. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.06.018
Vancouver
Formisano E, Vignati A, Bertolini A, Barreto Spandonari VM, Tafuro M, Pasta A, et al. Decline in LDL-C control in patients with dyslipidemia treated with PCSK9-inhibitors: The role of obesity in LDL-C target achievement. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.06.018
BibTeX
@article{Formisano2025,
author = {Formisano, Elena and Vignati, Andrea and Bertolini, Almina and Barreto Spandonari, Valeria Maria and Tafuro, Michele and Pasta, Andrea and Sukkar, Samir Giuseppe and Pisciotta, Livia},
title = {Decline in LDL-C control in patients with dyslipidemia treated with PCSK9-inhibitors: The role of obesity in LDL-C target achievement},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.06.018}
}
EUVIMED